ABSTRAa. Synthetic metalloporphyins inhibit formation of bilirubin by the heme oxygenase system, an ability that is of considerable experimental and clinical interest for suppression of jaundice in the newborn. The present investigation compares the consequences of treatment with Sn-and Zn-protoporphyrin on hemoprotein-dependent enzymes of the rat adrenals and corticosterone production and defines Sn-protoporphyrin as a potent toxin to adrenal functions. Treatment of rats with Sn-protoporphyrin (two doses of 50 pmol/kg, in 7 d) resulted in a marked reduction of 30-40% in cytochrome P-450-dependent adrenal microsoma1 2la-hydroxylase and mitochondrial llfl-hydroxylase activities. In the serum, the levels of corticosterone were reduced to about 70% of the control value. In addition, the mitochondrial cytochrome P -4 5 0 s~~ activity was decreased by about 50%. This decrease, however, could not be attributed to a reduced total heme level or an accelerated heme degradatory activity. Disruption by Sn-protoporphyrin of adrenal hemoprotein-dependent functions was not restricted to steroidogenic activities and encompassed drug metabolism activity of the organ; benzo(a)pyrene hydroxylase activity of both the microsomal and the mitochondrial fractions, as well as the microsomal NADPHcytochrome P-450 reductase activity, were significantly reduced. Zn-protoporphyrin did not cause significant alterations in the above measured parameters although it too was effective in inhibiting the hepatic microsomal heme oxygenase activity. In light of the presently defined adverse effects of Sn-~roto~orphyrin on adrenal steroidogenesis, we suggest ~n -~r o i o~~r i h~r i n is the agent of choice for ~otential use in treatment of hs~erbilirubinemia in humans.
Suppression of bilirubin production has been considered a desirable method for controlling severe cases of neonatal hyperbilirubinemia in premature babies or infants at high risk for severe postnatal jaundice. In this context, synthetic metalloporphyrins have recently become of interest to neonatologists because of their ability to suppress heme degradation by microsoma1 heme oxygenase (1-1 3) . This in turn reflects the function of heme oxygenase isozymes, HO-1 and HO-2 (14), to serve as the first and rate-limiting step in the pathway of heme degradation and bilirubin production (15, 16). As is well recognized, after parturition human neonates have transient deficiencies in the mechanisms involved in the disposal of bilirubin, which result, in certain instances, in critically high serum levels of the bile pigment and the need for clinical intervention.
When the ability of synthetic metalloporphyrins to inhibit in vivo heme oxygenase activity was first described (2), based on consideration of the relative toxicity of the various metalloporphyrins including Zn and Sn complexes, the suggestion was made that Zn-protoporphyrin is a relatively safer compound with potential usefulness to suppress heme oxygenase activity. However, among the various metalloporphrins that are now known capable of inhibiting heme oxygenase activity, only the clinical use of Sn-protoporphyrin has been actively promoted. The promotion is based on the seemingly superior efficiency of the complex to suppress heme oxygenase activity (4) and the assumption that this metalloporphyrin is rather safe and competitively inhibits the enzyme activity (3, 17, 18) . Indeed, recently the complex has been used on an experimental basis in humans, both infants and adults, with various disorders of heme metabolism (6, 9, 10, 12). The presumed safety, however, has been based on examining a relatively select spectrum of hepatic and renal hemoprotein-dependent drug metabolic activities and hematological parameters (1 7, 18) .
Drug biotransformation activities, however, are not the only heme dependent cellular processes. Metabolism of a variety of endogenous compounds is also hemoprotein dependent. For example, a number of catalytic steps in the biosynthesis of steroids are mediated by the hemoproteins, cytochromes P-450. For adrenals this includes the mitochondrial 1 lp-hydroxylase, cytochrome P-450scc (which catalyzes side-chain cleavage of cholesterol), and the microsomal 17a and 2 1 a-hydroxylases (1 9-24). As could be predicted, there exists an intimate relationship between the pathways of steroidogenesis and heme metabolism, wherein changes in heme biosynthesis and degradation are reflected in the concentration of cytochromes P-450 and ultimately in the production of steroids (25-29). In fact, rather recently, catalysis of the heme moiety of different cytochrome P-450 species by both heme oxygenase isozymes has been demonstrated in reconstituted systems (30).
The intimate relationship between heme metabolic activity and functions that depend on cytochrome P-450 promoted the present investigation to examine and compare the effect of Snand Zn-protoporphyrin on hemoprotein-dependent adrenal steroidogenesis. We have found that Sn-protoporphyrin is a potent inhibitor of steroidogenesis in the adrenals and adversely affects hemoprotein-dependent functions of this organ. In contrast, Znprotoporphyrin appears to be relatively innocuous in altering the assessed parameters. We suggest that Zn-protoporphyrin is the more desirable complex for suppression of bilirubin produ~ti'on in humans.
MATERIALS AND METHODS
Cofactors and steroids (progesterone, 17a-hydroxyprogesterone, 25-hydroxycholesterol, pregnenolone, 1 l-deoxycorticosterone, corticosterone) were obtained from Sigma Chemical Co. (St. Louis, MO). Sn-protoporphyrin-IX dichloride and Zn-protoporphyrin IX were obtained from Porphyrin Products (Logan, UT). Cyanoketone was a gift from the Sterling-Winthrop Laboratories (Rensselaer, NY). Pregnenolone antisera were purchased from Radioassay Systems Laboratories (Carson, CA). [7-3H] Pregnenolone was purchased from New England Nuclear (Boston, MA). All animal experimentation described in this study was performed with the highest standards of humane care according to the guidelines set forth by the National Institutes of Health.
Animal and tissue preparation. Adult male Sprague-Dawley rats (200-250 g) were obtained from Harlan Industries (Madison, WI) and were allowed access to food and water ad libitum. Rats were injected with either Sn-or Zn-protoporphyrin (50.0 pmol/ kg, s.c.) and 4 d later were given a second similar dose of the respective compound. These animals were killed 7 d after the first injection. In one series of experiments, rats were treated with the same dose of metalloprotoporphyrins and killed 6 h later. Control animals received saline. Shortly before use, 25.0-mM metalloprotoporphyrin solutions were prepared by dissolving the compounds in minimum volumes of 0.1 N NaOH and 95% ethanol. Subsequently, the solution was diluted with 0.9% (wt/ vol) NaCl and adjusted to pH 7.2-7.4 by the addition of 1.0 N NaOH. The volume of injection was 200 pL/100 g body weight.
Blood was obtained by cardiac puncture after the administration of 50.0 mg/kg sodium pentobarbital (intraperitoneally). Subsequently, the animals were decapitated and the organs were perfused in situ with saline. The adrenals were defatted and homogenized in 20 tissue volume of 10.0 mM Tris-HC1 buffer, pH 7.4, that contained 0.25 M sucrose (27). The mitochondrial and microsomal fractions were prepared by differential centrifugation as described previously (27). The hepatic microsomal fraction was obtained as detailed elsewhere (14).
The serum was assayed for the estimation of corticosterone. The adrenal mitochondrial fraction was assayed for cholesterol side-chain cleavage and 1 lp-hydroxylase activities and cytochrome P-450 and heme contents. The mitochondrial and microsomal fractions were assayed for benzo(a)pyrene hydroxylase, and the microsomal fraction was used for assessment of NADPHcytochrome P-450 reductase and 2la-hydroxylase activities. Heme oxygenase activity was measured in the liver and adrenal microsomal fractions. The experimental procedures described in the following sections were carried out under subdued lighting.
Enzyme assays on subcellular fractions. Benzo(a)pyrene hydroxylase activity was measured by the fluorometric procedure of Dehnen et al. (31) . NADPH-cytochrome P-450 reductase activity was determined by measuring the increase in absorbance at 550 nm due to the reduction of cytochrome c in the presence of NADPH (32) . The microsomal heme oxygenase activity was assessed as detailed previously (30). The activity of adrenal 2 1 ahydroxylase was determined by using a modification of the assay procedure described by Menard et al. (33) . Briefly, an incubation mixture (1.0 mL) consisting of 200 pg of adrenal microsomal protein, 150 pM progesterone, and 0.2 mM NADPH was incubated for 15 min at 37°C. The hydroxylated products were extracted into methylene chloride, evaporated to dryness, and subsequently redissolved in methanol. The products were analyzed by HPLC using a 246-nm wavelength for detection. A Waters 6000 LC system (Waters, Milford, MA) equipped with a Rheodyne 7025 injector (Rheodyne, Cotati, CA) with a 20-pL loop was used. The separations were performed using a 5-pm Zorbax ODs column (Dupont, Wilmington, DE) (4.6 mm x 25 cm) with an isocratic solvent system that was composed of 75% methanol in water at a flow rate of 1 mL/min. The system was operated at ambient temperature. The steroids were quantitated by comparing the sample peak area with that of the external standards.
Adrenal mitochondrial 1 ID-hydroxylase activity was estimated by measuring the rate of conversion of the substrate, deoxycorticosterone, to corticosterone (34) . The simultaneous additions of 10 mM D,L-isocitrate and 0.2 mM NADPH were used to initiate the reaction. The product was analyzed by HPLC using the same Zorbax column and an isocratic elution of 67.5% methanol in water at a flow rate of 1 mL/min. Detection was made spectrophotometrically at 246 nm and quantitated by use of the external standards.
Mitochondria1 cholesterol side-chain cleavage activity was determined as described previously (27) using the modified procedure of Mason et al. (35) . The assay system (1.0 mL) consisted of 0.1 mg of adrenal mitochondrial protein, 25-hydroxycholesterol (100 pM) and cyanoketone (6 pM). The reaction mixture was initiated by the simultaneous addition of 10 mM D,Lisocitrate and 0.2 mM NADPH. At 10 min, 500-pL aliquots were removed and used for extraction of the product, pregnenolone. Pregnenolone was subsequently measured by the RIA method of Abraham et al. (36) and quantitated using a standard curve for pregnenolone concentrations of 0.1-2.0 ng.
Spectral studies on subcellular fractions. The mitochondrial cytochrome P-450 was measured by the procedure previously described (28). The mitochondrial preparation (0.25 mg protein/ mL) was suspended in 20 mM Tris-HC1 buffer, pH 7.5, containing 1 mM EDTA, 20% glycerol, and 0.2% Emulgen 9 11 (KAO Atlas, Japan) and frozenlthawed one time. Sodium ascorbate and N,N,N',N'-tetramethylphenylenediamine (16 and 0.24 mM, final concentrations, respectively) were added to the suspension as reducing agents, and the mixture was incubated for 5 min at 30°C. The suspension was equally divided between two cuvettes. The test cuvette was bubbled with CO and the baseline was recorded. Thereafter, sodium dithionite was added to both cuvettes and the CO difference spectrum was recorded. An extinction coefficient of 9 1 cm-' . mM-I was used for calculation of the hemoprotein content. Total heme concentration was measured by the pyridine hemochromogen method of Paul et al. (37) .
The protein concentration was determined by the method of Lowry et al. (38) with BSA as the protein standard.
Determinations of serum corticosterone. The determination of serum concentration of corticosterone was performed by a modification of the procedure of Stoks and Benraad (39) . Briefly, 1-mL aliquots of serum were extracted with 5.0 mL of methylene chloride. Subsequently, the organic phase was separated and evaporated to dryness, and the residue was reconstituted with methanol. The extracts were analyzed by the HPLC procedure that was described above for 1 I@-hydroxylase assay.
Data analysis. The data were analyzed using nonpaired t test with a two-tailed t distribution; a value ofp 5 0.05 was considered to denote significance. The data are the mean k SD; the number of determinations are indicated in appropriate tables and figures. One or two rats were used for each determination. to about 40% of the control value. In contrast, in Zn-protoporphyrin-treated animals neither activity was altered. To examine the ramification of these changes in steroid hydroxylase activities, serum corticosterone levels were measured. The findings that are shown in Figure 2 denote a significant reduction in serum corticosterone levels in Sn-protoporphyrin-treated rats. As could have been predicted, Zn-protoporphyrin did not exert an effect on serum glucocorticoid levels.
To further explore the effect of the metalloporphyrins on adrenal steroidogenesis, the mitochondrial cytochrome P-450 content and side-chain cleavage activity were assessed. Data are shown in Figure 3 . As shown, a marked reduction of nearly 50% in the cytochrome P-450 content was detected in preparations obtained from Sn-protoporphyrin-treated animals. Again, Znprotoporphyrin did not affect the hemoprotein level. The cholesterol side-chain cleavage activity as assessed by pregnenolone U CONTROL Fig. 3 . Effect in vivo of Zn-and Sn-protoporphyrin on adrenal mitochondrial contents of cytochrome P-450 and side-chain cleavage activity. Rats were treated with two doses of metalloporphyrins as detailed in Materials and Methods. The adrenal mitochondrial fraction was prepared as detailed previously (27) and used for assessment of cytochrome P450scc content and the rate of side-chain cleavage activity. The control value for cytochrome P-450 was 8 17 k 93 pmol/mg protein. Methods used for enzyme assays are described in detail in the text. The data shown are the mean + SD of six to eight determinations per treatment group.
The pooled adrenals from two rats were used for each determination.
An asterisk indicates p s 0.05 when compared with the control group. Fig. 4 . Response of adrenal heme oxygenase and NADPH-cytochrome P-450 reductase activities and total mitochondrial heme content to Zn-and Sn-protoporphyrin treatments. Adrenals were obtained from rats treated with synthetic metalloporphyrins (50 pmol/kg, twice) and used for subcellular fractionation. The microsomal preparation was used for measurement of heme oxygenase and NADPH-cytochrome P-450 reductase activities and the mitochondrial fraction was used for assessment of total heme content by the pyridine hemochromogen method (37) formation, however, was not significantly altered in Sn-protoporphyrin-treated animals.
CONTROL
The underlying basis for decrease in cytochrome P-450 was examined by measuring total mitochondrial heme concentration. As noted in Figure 4 , a decrease in heme content was not detected, suggesting that modulation in the hemoprotein concentration was not a result of an overall decrease in cellular concentrations of the heme prosthetic moiety. Furthermore, the decrease in the cytochrome level did not reflect an accelerated rate of cellular heme degradation because the activity of heme oxygenase was severely decreased in Sn-protoporphyrin-treated animals (Fig. 4) . Zn-protoporphyrin also caused a modest but significant decrease in heme oxygenase activity. The activity of heme oxygenase requires the concerted activity of the oxygenase and NADPH-cytochrome P-450 reductase; therefore, the possibility was examined that the observed inhibition of bilirubin formation DISCUSSION by metalloporphyrins may be due to an inhibited reductase activity. The results of this investigation are also shown in Figure  4 . As shown, Sn-protoporphyrin significantly inhibited the reductase activity. The magnitude of inhibition, which measured about 30%, could contribute to the observed depression in bilirubin formation by the heme oxygenase system; Zn-protoporphyrin treatment did not affect the reductase activity.
To determine whether the observed perturbations were restricted to steroid hydroxylation processes or extended to other biotransformations that depend on cytochrome P-450, hydroxylation of the prototype drug, benzo(a)pyrene, by the adrenals of the metalloporphyrin-treated animals was examined. Data are shown in Table 1 . As noted, drug hydroxylation by both the mitochondrial and the microsomal fractions of Sn-protoporphyrin-treated rats was significantly decreased. The decrease in the microsomal activity was particularly notable wherein activity was decreased by more than 45%. The activity of the mitochondrial fraction was decreased by about 20%. Because the microsoma1 drug hydroxylation also requires the concerted activity of NADPH-cytochrome P-450 reductase, the depression of the reductase activity (Fig. 4) could be, in part, responsible for this observation. In Zn-protoporphyrin-treated rat adrenals, significant alterations in benzo(a)pyrene hydroxylase activities of the microsomal or mitochondrial fraction were not detected.
To examine the acute effectiveness of the metalloporphyrins to inhibit bilirubin production by the adrenals as well as in other organs, the adrenal and hepatic heme oxygenase activity of animals treated once with the metalloporphyrins and killed 6 h later was examined (Table 2 ). In the adrenals of treated rats, the enzyme activity was not severely affected by the metalloporphyrins; however, in the liver, activity was essentially undetectable in Sn-protoporphyrin-treated rats, whereas it was inhibited by about 55% in the Zn-protoporphyrin-treated animals. When the ability of metalloporphyrins to inhibit in vivo heme oxygenase activity was first discovered (2), although both Snand Zn-protoporphyrins were found to be effective, the potential use of the Zn-protoporphyrin but not of the tin complex was suggested as a possible means to obviate the postparturition surge in serum bilirubin levels. This suggestion was based on considerations of the molecular properties of the two metalloporphyrins, as well as the apparent selectivity of Zn-protoporphyrin to inhibit the hepatic heme oxygenase activity, albeit only a few drug metabolic parameters were examined at that time (2) . The subsequent reports (3, 4) on the superior efficiency of Sn-protoporphyrin to inhibit heme oxygenase rapidly culminated in clinical testing of the tin complex in humans, including newborn infants, to suppress production of bilirubin (9, 10, 12); it was assumed that Sn-protoporphyrin is a safe and selective inhibitor of the enzyme. Again the assumption of safety was for the most part based on limited findings mainly obtained by assessing a narrow spectrum of hepatic cytochrome P-450-dependent drug metabolism and hematologic parameters (7, 9, 17, 18) . The selected parameters apparently were nonresponsive to the Snprotoporphyrin, because long-term administration of massive doses (100 pmol/kg/wk) of the metalloporphyrin for up to 32 wk or treatment of animals for five consecutive d with large doses of 100 pmol/kg of the metalloporphyrin complex was reported not to have appreciable adverse effects on activities of several enzymes of heme biosynthesis in the liver, contents of hepatic and renal microsomal cytochrome P-450, or hematologic indices such as red blood cell count, Hb and protoporphyrin concentrations, and hematocrit (17). The findings of that study, however, contrasted those of another investigation that reported on the diminished capacity of the hepatic microsomal fraction of juvenile rats treated with Sn-protoporphyrin (50 pmol/kg/d for 6 d) to cany out mixed-function oxidase activities (40) .
The results of the present study clearly show that those hemoprotein species that are present in the steroidogenic organ, the adrenals, are highly susceptible to adverse effects of Snprotoporphyrin. In this organ, activities of both the microsomal 2la-hydroxylase and the mitochondrial 1 lp-hydroxylase were severely inhibited (Fig. I) . Insofar that the adrenal cortex is the site of glucocorticoid production, as would be predicted, a significant decrease in serum glucocorticoid, corticosterone, was noted as the result of metalloporphyrin treatment (Fig. 2) . In addition, the general ability of the organ to carry on cytochrome P-450-dependent biotransformations, as reflected by the metabolism of the prototype drug, benzo(a)pyrene, was significantly curtailed in both the mitochondrial and the microsomal fractions (Table I ). The present study also finds that Zn-protoporphyrin, by and large, does not affect the assessed parameters, although it effectively inhibits heme oxygenase activity.
The observation with adrenals where the concentration of cytochrome P-450 (Fig. 3) was decreased but the decrease was not reflected in side-chain cleavage activity resembles what we have observed in the past with gonadotropin-releasing hormone and human chorionic gonadotropin effects on testis; both hormones cause significant increases in cholesterol side-chain cleavage activity without a concomitant increase in cytochrome P-450 content. These observations, in turn, are analogous to the reported action of ACTH that causes an increase in cytosolic peptide in the adrenal cortex, which in turn increases the rate of association of cholesterol with cytochrome P-450scc and stimulates side-chain cleavage activity without increasing the levels of the cytochrome (23). Accordingly, it is plausible that the presently observed absence of a decrease in side-chain cleavage activity of the adrenal mitochondria, in the face of a significant decrease in cytochrome P-450 content, may also reflect an increased association of substrate with the enzyme. Moreover, the underlying basis for decrease in the hemoprotein level appears not to involve a decrease in synthesis or increased degradation
